ArticleNature medicine2019
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Erratum issued 2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 424 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
424citing papers in PubMed, 1 pooled it
63.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer
Who cites it
424 citing papers in PubMed, 1 synthesis or guideline pooled it, 635 citations in OpenAlex.
- The safety and efficacy of binimetinib for lung cancer: a systematic review.BMC pulmonary medicine · 2024Pooled it
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.JCO precision oncology · 2025Trial
- A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.The oncologist · 2023Trial
- Practical management of BRAF inhibitors in glioma: toxicity and resistance.CNS oncology · 2026Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Lysosomal metabolism in pancreatic cancer and its crosstalk with host physiology.Genes & development · 2026Review
- Drugging small-molecule compounds in autophagy-dependent cell death to overcome cancer therapy resistance.Apoptosis : an international journal on programmed cell death · 2026Review
- Review
- Canonical lymphocyte chemokine receptors CXCR3 and CXCR5 modulate neuronal autophagy.Cell death and differentiation · 2026Article
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Autophagy Orchestrates Anti-Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP-2 Axis in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.bioRxiv : the preprint server for biology · 2026Article
- Small-molecule autophagy modulators: Mechanisms, therapeutic potential, and development challenges in pathological settings.Fundamental research · 2026Review
- Autophagy-Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting.Cancers · 2026Review
- Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review).International journal of oncology · 2026Review
- Molecular Determinants of Thyroid Cancer Progression: Thyroid Hormone Signaling, the BRAF/MAPK Pathway, and Emerging miRNA Biomarkers.Biomedicines · 2026Review
- Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.Cancer research · 2026Article
- Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment.Molecular cancer · 2026Review
364 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
23 authors at 2 institutions in 2 countries.
Conan G KinseyHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Soledad A CamolottoHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Amelie M BoespflugHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Katrin P GuillenHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Mona FothHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0001-6507-8114
Amanda TruongHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Sophia S SchumanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jill E SheaDepartment of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Michael T SeippDepartment of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Jeffrey T YapHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Lance D BurrellHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
David H LumHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jonathan R WhisenantHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
G Weldon GilcreaseHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Courtney C CavalieriHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Kaitrin M RehbeinHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Stephanie L CutlerHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Kajsa E AffolterHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Alana L WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Bryan E WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Courtney L ScaifeHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Eric L SnyderHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Martin McMahonHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. martin.mcmahon@hci.utah.edu.ORCID http://orcid.org/0000-0003-2812-1042
University of Utah · USUniversité Claude Bernard Lyon 1 · FR
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MDEVELOPMENTAL BIOLOGY TRAINING PROGRAMT32HD007491 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI James Alan Gagnon, Kristen M Kwan · 1995 to 2026
$8.0MStudying the initiation, progression and therapy of lung cancer in mouse modelsR01CA131261 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2009 to 2026
$5.3MTranscriptional Regulation of Lung Cancer IdentityR01CA212415 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Eric Lee Snyder · 2017 to 2026
$3.2MTargeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma TherapyR01CA176839 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MARTIN MCMAHON · 2013 to 2026
$2.9MDefining the role of aberrant signal pathway activation in melanoma on the immune microenvironmentF30CA235964 · NCI · UNIVERSITY OF UTAH · PI TRUONG, AMANDA · 2019 to 2021
$136kNCI NIH HHS F30 CA235964NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA131261NCI NIH HHS R01 CA176839NCI NIH HHS R01 CA212415NCI NIH HHS U54 CA224076NICHD NIH HHS T32 HD007491
Abstract
Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS
Indexed as
AnimalsAutophagyCA-19-9 AntigenCell Line, TumorChloroquineHumansMAP Kinase Signaling SystemMice, SCIDMitogen-Activated Protein Kinase KinasesPancreatic NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesras ProteinsXenograft Model Antitumor AssaysCA-19-9 AntigenChloroquineMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesras Proteinstrametinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02704156ClinicalTrials.gov
NCT03825289ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.